CAS NO: | 1400989-25-4 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | SC-43, a Sorafenib derivative, is a potent and orally activeSHP-1 (PTPN6)agonist. SC-43 inhibits the phosphorylation ofSTAT3and induces cellapoptosis. SC-43 has anti-fibrotic and anticancer effects[1][2]. | ||||||||||||||||||||||||
IC50& Target[1][2] |
| ||||||||||||||||||||||||
体外研究 (In Vitro) | SC-43 (0-10 μM; 24-72 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment reveals the anti-proliferative effects in cholangiocarcinoma (CCA) cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively[1]. Cell Viability Assay[1]
Cell Cycle Analysis[1]
Western Blot Analysis[1]
| ||||||||||||||||||||||||
体内研究 (In Vivo) | SC-43 (10-30 mg/kg; oral gavage; daily; for 23 days; male NCr athymic nude mice) treatment exhibits xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation[1].
| ||||||||||||||||||||||||
Clinical Trial | |||||||||||||||||||||||||
分子量 | 431.80 | ||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||
Formula | C21H13ClF3N3O2 | ||||||||||||||||||||||||
CAS 号 | 1400989-25-4 | ||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||
储存方式 |
| ||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : 250 mg/mL(578.97 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|